Edwards Lifesciences (XSWX:EW) Research & Development: CHF867 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:EW Edwards Lifesciences Corp XSWX:EW
98 GF Score
Price CHF72.07
GF Value CHF75.68
! 5 Warning Signs
View Full Analysis

What is Edwards Lifesciences Research & Development?

Edwards Lifesciences XSWX:EW 98 Research & Development is CHF867 Mil as of Jun. 2026. GuruFocus rates XSWX:EW with a GF Score™ of 98/100 and a GF Value™ of CHF75.68. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Edwards Lifesciences's Research & Development for the three months ended in Jun. 2026 was CHF223 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was CHF867 Mil.

Edwards Lifesciences  (XSWX:EW) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Edwards Lifesciences Research & Development Related Terms

Edwards Lifesciences Research & Development Historical Data

* Premium members only.

The historical data trend for Edwards Lifesciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edwards Lifesciences Research & Development Chart

Edwards Lifesciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 831.76 785.90 832.72 938.86 860.01

Edwards Lifesciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 224.61 223.47 213.33 207.30 222.93
XSWX:EW
98GF Score
Edwards Lifesciences Corp XSWX:EW
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edwards Lifesciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF867 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of CHF867 Mil mean?
Edwards Lifesciences (XSWX:EW) has a Research & Development of CHF867 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Edwards Lifesciences and its competitors.
Is Edwards Lifesciences' Research & Development too high?
Edwards Lifesciences' current Research & Development is CHF867 Mil. Overall, Edwards Lifesciences has a GF Score™ of 98/100, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' Research & Development compare to BSX and DXCM?
Edwards Lifesciences' Research & Development of CHF867 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Edwards Lifesciences and its competitors. Edwards Lifesciences's current Research & Development is CHF867 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Edwards Lifesciences (XSWX:EW) has a current Research & Development of CHF867 Mil. The stock's GF Value™ is CHF75.68, compared to a current price of CHF72.07 — trading 4.8% below its estimated fair value. The current Research & Development is CHF867 Mil. Edwards Lifesciences' overall GF Score™ is 98/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Edwards Lifesciences (XSWX:EW), the current Research & Development is CHF867 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Edwards Lifesciences (XSWX:EW) Overvalued in 2026?

Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued. The current stock price of CHF72.07 is trading 4.8% below its estimated GF Value™ of CHF75.68.

Key valuation signals for XSWX:EW:

  • Research & Development: CHF867 Mil
  • GF Value™: CHF75.68 vs. price of CHF72.07 (4.8% below fair value)
  • GF Score™: 98/100 with 5 warning signs

No single metric tells the full story. See the XSWX:EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Edwards Lifesciences Business Description

Address One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
98GF Score

Get the complete analysis for XSWX:EW

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF72.07
Price
CHF75.68
GF Value